BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/18/2023 5:48:01 AM | Browse: 208 | Download: 635
 |
Received |
|
2022-09-21 08:25 |
|
Peer-Review Started |
|
2022-09-21 08:26 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-10-19 13:06 |
|
Revised |
|
2022-10-29 03:18 |
|
Second Decision |
|
2022-12-21 03:33 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-12-21 09:01 |
|
Articles in Press |
|
2022-12-21 09:01 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-12-18 09:48 |
|
Typeset the Manuscript |
|
2023-01-09 17:57 |
|
Publish the Manuscript Online |
|
2023-01-18 05:48 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jiang Li, Fan Yang, Jian Li, Zhi-Yong Huang, Qi Cheng and Er-Lei Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81902839 |
|
| Corresponding Author |
Er-Lei Zhang, MD, PhD, Doctor, Doctor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Dadao, Wuhan 430030, Hubei Province, China. baiyu19861104@163.com |
| Key Words |
Microvascular invasion; Hepatocellular carcinoma; Liver resection; Liver transplantation; Postoperative; Adjuvant treatment |
| Core Tip |
Microvascular invasion (MVI) is considered to be one of the important prognostic factors affecting postoperative recurrence and long-term survival. Unfortunately, whether hepatocellular carcinoma (HCC) patients with MVI should receive postoperative adjuvant therapy remains unknown. In this review, we summarize the therapeutic effects of transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine protein kinase inhibitor-based targeted therapy, and immune checkpoint inhibitors in patients with MVI after liver resection (LR) or liver transplantation (LT), aiming to provide a reference for the best adjuvant treatment strategy for HCC patients with MVI after LT or LR. |
| Publish Date |
2023-01-18 05:48 |
| Citation |
Li J, Yang F, Li J, Huang ZY, Cheng Q, Zhang EL. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World J Gastrointest Surg 2023; 15(1): 19-31 |
| URL |
https://www.wjgnet.com/1948-9366/full/v15/i1/19.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v15.i1.19 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
